Valneva (VALN) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Valneva is set to release its Q2 2025 earnings report on August 12th, with analysts predicting a loss of $0.27 per share and revenue of $46.28 million.
• In the previous quarter, Valneva reported a loss of $0.13 per share and revenue of $51.79 million, outperforming estimates of a larger loss.
• Valneva's stock price increased by 2.5%, and the company currently has a market capitalization of approximately $653.92 million.

Valneva (NASDAQ:VALN - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Valneva to post earnings of ($0.27) per share and revenue of $46.28 million for the quarter.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.27. The business had revenue of $51.79 million for the quarter, compared to analysts' expectations of $41.80 million. Valneva had a negative net margin of 43.08% and a negative return on equity of 43.05%. On average, analysts expect Valneva to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Valneva Trading Up 10.4%

NASDAQ:VALN traded up $0.86 during trading hours on Friday, hitting $9.11. The company had a trading volume of 185,104 shares, compared to its average volume of 56,845. The company has a market capitalization of $775.17 million, a PE ratio of -7.66 and a beta of 1.77. The stock has a 50-day moving average price of $6.47 and a 200 day moving average price of $6.57. Valneva has a 52 week low of $3.62 and a 52 week high of $9.13. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.70 and a quick ratio of 2.12.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Valneva in a report on Tuesday, April 15th. Guggenheim dropped their target price on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, May 8th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.